TNFRSF9 and melanoma: The overall survival rate of patients with high expressions of CCR7, CXCR5, EOMES, GBP4, TNFRSF9 and STAT1 in melanoma was significantly higher (Figure 5C–H), which is consistent with the significantly higher survival rate observed for the young cohort receiving immunotherapy (Figure 1B).